myeloid and T cell depletor
ELA026 is a monoclonal antibody specifically designed to address severe inflammatory disorders with aberrant myeloid and T cell activity. It induces rapid, potent, and targeted depletion of the circulating myeloid and T cells that drive inflammation, without disrupting the SIRPα/CD47 immune checkpoint function.
and in preclinical development for other inflammatory diseases.
TREATING sHLH
OFFERING HOPE
sHLH is a life-threatening hyperinflammatory condition for which there is no approved treatment. sHLH can occur at any age. Once triggered, sHLH requires immediate intervention. Without treatment, it can rapidly progress from symptoms such as persistent fever, hepatomegaly and/or splenomegaly, and cytopenias, to multiorgan failure and death.¹,² Our first-in-class SIRP-directed monoclonal antibody, ELA026, has the potential to be a life-changing treatment for patients with sHLH.
PATHOGENESIS OF sHLH
By targeting SIRP on the cell surface of myeloid and T cells,
ELA026 DEPLETES THE CELLS RESPONSIBLE FOR INDUCING THE HYPERINFLAMMATORY CONDITION IN sHLH.
By targeting SIRP on the cell surface of myeloid and T cells,
ELA026 DEPLETES THE CELLS RESPONSIBLE FOR INDUCING THE HYPERINFLAMMATORY CONDITION IN sHLH.
sHLH is a life-threatening disease in
need of effective treatments.
ELA026 HAS THE POTENTIAL TO BE A TRANSFORMATIVE TREATMENT FOR PATIENTS WITH sHLH.
Expanded Access to Investigational Medicines Prior to Regulatory Approval
At Electra Therapeutics, we aim to provide patients access to our investigational therapies in the most clinically appropriate manner. Electra Therapeutics does not currently accept or grant requests for expanded access to any of our investigational therapies outside of clinical trials.
References: 1. Otrock Z, Eby C. Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol. 2015;90(3):220-224. doi:10.1002/ajh.23911 2. Trottestam H, Horne A, Aricò M, et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 2011;118(17):4577-4584. doi:10.1182/blood-2011-06-356261 3. Bergsten E, Horne A, Arico M, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017;130(25):2728-2738. doi:10.1182/blood-2017-06-788349 4. Yoon JH, Park SS, Jeon YW, et al. Treatment outcomes and prognostic factors in adult patients with secondary hemophagocytic lymphohistiocytosis not associated with malignancy. Haematologica. 2019;104(2):269-276.doi:10.3324/haematol.2018.198655
201 Haskins Way, 5th Floor
South San Francisco, CA 94080
888-743-2290
info@electra-therapeutics.com
© 2024 Electra Therapeutics Inc.